Selumetinib

證據等級: L5

預測適應症: 10 個

One-Sentence Summary

Selumetinib is a MEK1/2 inhibitor whose established use — noted in the evidence pack’s rationale text rather than the structured drug profile — is NF1-related plexiform neurofibroma; formal original-indication and mechanism-of-action fields are flagged as data gaps in this pack. The TxGNN model’s top prediction is Familial Generalized Lentiginosis, but this specific prediction currently has 0 clinical trials and 0 publications supporting it — it is a model-score-only candidate.

Quick Overview

Item	Content
Original Indication	NF1-related plexiform neurofibroma (sourced from repurposing-rationale text; not present in structured `original_indications` field — data gap DG002 relates)
Predicted New Indication	Familial Generalized Lentiginosis
TxGNN Prediction Score	99.96%
Evidence Level	L5 (model prediction only, no supporting trials/literature)
US Market Status	Not Marketed (未上市)
Number of NDAs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism-of-action data is not available in this evidence pack (marked as a High-severity data gap, DG002). Based on information embedded in the pack’s own rationale text, Selumetinib is understood to be a MEK1/2 inhibitor, and its use in NF1-related plexiform neurofibroma is referenced as an established application of this drug class.

Familial generalized lentiginosis belongs to the multiple-lentigines/RASopathy disease group, which can involve overlapping germline genes (e.g., PTPN11) that sit upstream in the RAS–RAF–MEK–ERK signaling cascade. Since MEK inhibitors act directly downstream of this pathway, there is a plausible mechanistic rationale for testing selumetinib in RASopathy-spectrum conditions.

That said, the evidence pack explicitly states this rationale is “purely a TxGNN prediction score, with no clinical or literature support” (from the pack’s own rank-1 rationale text). The mechanistic plausibility is real, but it remains theoretical for this specific indication.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

US Market Information

Selumetinib currently has no NDA or marketing authorization on file in this evidence pack — market status is recorded as “未上市” (Not Marketed) with 0 total licenses. No product/dosage-form/indication data is available to tabulate.

Cytotoxicity

Selumetinib is a targeted small-molecule kinase inhibitor (MEK1/2), used in the oncology/RASopathy space based on the evidence pack’s rationale references; several of the drug’s other predicted indications in this pack are neoplasms (rhabdoid tumor, peripheral nerve schwannoma), supporting its classification here.

Item	Content
Cytotoxicity Classification	Targeted therapy (MEK1/2 inhibitor)
Myelosuppression Risk	Please refer to the package insert warnings and precautions
Emetogenicity Classification	Please refer to the package insert warnings and precautions
Monitoring Items	Please refer to the package insert warnings and precautions
Handling Protection	Please refer to the package insert warnings and precautions

Safety Considerations

Please refer to the package insert for safety information. (All key warnings, contraindications, and drug-interaction fields in this evidence pack are marked as data gaps; DG001 flags this as a Blocking gap that prevents entry into S1 safety review.)

Conclusion and Next Steps

Decision: Hold

Rationale: The top-ranked prediction (familial generalized lentiginosis) has zero clinical trial or literature support and is explicitly labeled L5/model-prediction-only in the evidence pack itself. Combined with the blocking safety data gap (no TFDA/package-insert warnings available) and the drug’s unmarketed US status, there is currently no basis to advance this specific indication.

To proceed, the following is needed:

Package insert / regulatory label data (warnings, contraindications) — currently blocking (DG001)
Confirmed mechanism-of-action documentation from DrugBank (DG002)
Any preclinical or clinical evidence specific to familial generalized lentiginosis or the broader RASopathy/lentiginosis spectrum
Formal original-indication records for Selumetinib (currently only inferable from rationale text, not a structured field)

Note on portfolio prioritization: Within this same evidence pack, rank 9 — peripheral nerve schwannoma carries substantially stronger evidence (L3, one Phase 2 trial with direct NF2-schwannoma relevance plus 7 supporting publications including a preclinical MEK/ERK mechanistic study) and may warrant separate evaluation ahead of the top-ranked candidate discussed here.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.